United States of America Viscosupplementation Market SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

United States of America Viscosupplementation Market Size - Analysis

The United States of America Viscosupplementation Market is estimated to be valued at USD 1.67 Bn in 2025 and is expected to reach USD 2.92 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2032.

United States of America Viscosupplementation Market Trends

The growing opioid addiction crisis in the United States is having a significant impact on driving the growth of the viscosupplementation market in the country. As per the data shared by the United States Centers for Disease Control and Prevention (CDC), over 100,000 Americans lost their lives due to drug overdose in 2021 alone, with majority of the deaths being attributed to synthetic opioids. The current opioid epidemic began in the late 1990s and continues to ravage communities across America.

Increasing awareness about opioid dependence treatment is significantly driving the growth of United States of America Viscosupplementation Market. As people are becoming more aware about the addictive nature and long-term health consequences of opioid dependence, they are looking for better treatment options. Viscosupplementation injections have proved to be very effective in managing pain associated with osteoarthritis of the knees without any risks of dependence or addiction.

With growing concerns around opioid crisis, healthcare providers are also increasingly recommending viscosupplementation injections to their patients dealing with chronic knee pain.

Stringent regulations for prescribing buprenorphine are presenting challenges for the growth of the viscosupplementation market in the United States. Buprenorphine is a critical treatment option for opioid addiction but the regulations make it difficult for physicians to prescribe. Data from 2019 showed over 47,000 drug overdose deaths involved opioids, demonstrating the continued severity of the addiction crisis. However, the regulations limit the number of patients a physician can treat with buprenorphine to just 30-275 based on experience level.

Viscosupplementation products in the United States currently face barriers when reaching patients who could benefit from their use. These products, which are injected to supplement decreased viscosity of the synovial fluid in osteoarthritic knees, rely on strong distribution networks to connect manufacturers with healthcare providers. However, distribution is often fragmented regionally. Consolidating distribution under larger networks with a national reach could help increase adoption of viscosupplementation across the country.

A focus on enhancing technology integration along the supply chain would also boost distribution opportunities. Distributors that offer providers convenient e-commerce platforms to order products will see greater order volumes processed more efficiently.

Segmental Analysis of United States of America Viscosupplementation Market

Insights, By Dosage: Convenience and Cost-Effectiveness Drive Single Injection Share

Within the US viscosupplementation market based on dosage, the single injection segment holds the largest share of 40.7%. This is primarily due to factors of convenience and cost-effectiveness for patients and physicians. Receiving treatment via a single administration reduces the number of medical visits and time commitment compared to multiple injections over weeks. For those suffering from osteoarthritis joint pain, minimizing additional doctor appointments provides relief.

Consumers show a strong preference for single treatment options whenever feasible across various medical needs. The convenience of one-and-done administration addresses compliance issues that can arise with multi-visit therapies. This empowers patients to proactively manage their condition without the hassle of scheduling and traveling to multiple follow-up injections. Such ease-of-use lifts treatment satisfaction and adherence, important outcomes particularly for symptomatic relief of a chronic condition.

The rheumatoid arthritis segment holds the largest share of 52.4% in the US viscosupplementation market when analyzed by condition type. This primacy stems directly from higher disease prevalence rates versus osteoarthritis within the country's population.

Preserving quality of life and economic participation provides strong motivation for effective RA symptom management. Viscosupplementation injections supplement depleted natural joint lubrication to ease pain and improve mobility. As a non-opioid and non-surgical option, they expand treatment choices for rheumatologists and patients. Their ability to quickly relieve flared RA symptoms and complement disease-modifying drug regimens also supports market demand.

Competitive overview of United States of America Viscosupplementation Market

The major players operating in the United States of America Viscosupplementation Market include Anika Therapeutics Inc., Ferring Pharmaceuticals, Bioventus, Fidia Farmaceutici S.P.A., Mylan N.V., Sanofi S.A., Teva Pharmaceutical Industries Ltd, Johnson & Johnson., F. Hoffmann-La Roche AG, and Zimmer Biomet.

Recent Developments in United States of America Viscosupplementation Market

United States of America Viscosupplementation Market Segmentation

• By Dosage
  • Single Injection
  • Three Injection
  • Five Injection
• By Arthritis Type
  • Osteoarthritis
  • Rheumatoid Arthritis
• By End User
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others